Cargando…

Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

BACKGROUND: The emergence of olaparib, a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor to treat metastatic castration-resistant prostate cancer (mCRPC), created a measurable clinical question on whether the agent positively influences the treatment outcomes and acceptable saf...

Descripción completa

Detalles Bibliográficos
Autores principales: Warli, Syah Mirsya, Velaro, Adrian Joshua, Firsty, Naufal Nandita, Tala, Zaimah Zulkarnaini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681786/
https://www.ncbi.nlm.nih.gov/pubmed/38022404
http://dx.doi.org/10.14740/wjon1685
_version_ 1785142623096274944
author Warli, Syah Mirsya
Velaro, Adrian Joshua
Firsty, Naufal Nandita
Tala, Zaimah Zulkarnaini
author_facet Warli, Syah Mirsya
Velaro, Adrian Joshua
Firsty, Naufal Nandita
Tala, Zaimah Zulkarnaini
author_sort Warli, Syah Mirsya
collection PubMed
description BACKGROUND: The emergence of olaparib, a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor to treat metastatic castration-resistant prostate cancer (mCRPC), created a measurable clinical question on whether the agent positively influences the treatment outcomes and acceptable safety factors. The objective was to elaborate on the efficacy and safety of olaparib-added regimens in treating mCRPC patients as compared to the established guideline. METHODS: The literature search was performed on several scientific databases, e.g., PubMed, Cochrane, and ScienceDirect, by applying the Boolean Term method. Statistical and risk of bias (RoB) analyses were calculated through RevMan 5.4.1. to investigate our outcomes, i.e., progression-free survival (PFS) and overall survival (OS) with the reported adverse effects (AEs). These outcomes were presented in hazard ratio (HR) and risk ratio (RR). RESULTS: Three trials consisting of 1,325 individuals with comparable baseline characteristics were investigated. The meta-analysis showed that introducing olaparib into the regimens significantly improved the PFS (HR 0.59 (0.48 - 0.73); P < 0.05), which disclosed even better outcomes among mutated homologous recombinant repair (HRR) and ataxia-telangiectasia mutated (ATM) gene (HR 0.43 (0.30 - 0.62); P < 0.05) in 95% confidence interval (CI). Furthermore, similar outcomes were observed in OS analysis (HR 0.81 (0.67 - 0.99); P < 0.05), despite olaparib group disclosed higher AEs rate with insignificant difference in mortality rate. CONCLUSION: The efficacy and safety of olaparib-added regimens in mCRPC patients need to be explored more extensively in trials because they are beneficial, particularly among HRR-mutated individuals.
format Online
Article
Text
id pubmed-10681786
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-106817862023-10-21 Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis Warli, Syah Mirsya Velaro, Adrian Joshua Firsty, Naufal Nandita Tala, Zaimah Zulkarnaini World J Oncol Original Article BACKGROUND: The emergence of olaparib, a poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor to treat metastatic castration-resistant prostate cancer (mCRPC), created a measurable clinical question on whether the agent positively influences the treatment outcomes and acceptable safety factors. The objective was to elaborate on the efficacy and safety of olaparib-added regimens in treating mCRPC patients as compared to the established guideline. METHODS: The literature search was performed on several scientific databases, e.g., PubMed, Cochrane, and ScienceDirect, by applying the Boolean Term method. Statistical and risk of bias (RoB) analyses were calculated through RevMan 5.4.1. to investigate our outcomes, i.e., progression-free survival (PFS) and overall survival (OS) with the reported adverse effects (AEs). These outcomes were presented in hazard ratio (HR) and risk ratio (RR). RESULTS: Three trials consisting of 1,325 individuals with comparable baseline characteristics were investigated. The meta-analysis showed that introducing olaparib into the regimens significantly improved the PFS (HR 0.59 (0.48 - 0.73); P < 0.05), which disclosed even better outcomes among mutated homologous recombinant repair (HRR) and ataxia-telangiectasia mutated (ATM) gene (HR 0.43 (0.30 - 0.62); P < 0.05) in 95% confidence interval (CI). Furthermore, similar outcomes were observed in OS analysis (HR 0.81 (0.67 - 0.99); P < 0.05), despite olaparib group disclosed higher AEs rate with insignificant difference in mortality rate. CONCLUSION: The efficacy and safety of olaparib-added regimens in mCRPC patients need to be explored more extensively in trials because they are beneficial, particularly among HRR-mutated individuals. Elmer Press 2023-12 2023-10-21 /pmc/articles/PMC10681786/ /pubmed/38022404 http://dx.doi.org/10.14740/wjon1685 Text en Copyright 2023, Warli et al. https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Warli, Syah Mirsya
Velaro, Adrian Joshua
Firsty, Naufal Nandita
Tala, Zaimah Zulkarnaini
Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title_full Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title_fullStr Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title_full_unstemmed Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title_short Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
title_sort addition of olaparib to the new hormonal agent regimen for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681786/
https://www.ncbi.nlm.nih.gov/pubmed/38022404
http://dx.doi.org/10.14740/wjon1685
work_keys_str_mv AT warlisyahmirsya additionofolaparibtothenewhormonalagentregimenformetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis
AT velaroadrianjoshua additionofolaparibtothenewhormonalagentregimenformetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis
AT firstynaufalnandita additionofolaparibtothenewhormonalagentregimenformetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis
AT talazaimahzulkarnaini additionofolaparibtothenewhormonalagentregimenformetastaticcastrationresistantprostatecancerasystematicreviewandmetaanalysis